

26100511D

1 **HOUSE BILL NO. 232**

2 Offered January 14, 2026

3 Prefiled January 8, 2026

4 *A BILL to amend and reenact § 54.1-3300.1 of the Code of Virginia, relating to collaborative agreements;*
5 *practitioners; diagnosis.*

6 Patron—Wachsmann

7 Committee Referral Pending

8 **Be it enacted by the General Assembly of Virginia:**9 **1. That § 54.1-3300.1 of the Code of Virginia is amended and reenacted as follows:**10 **§ 54.1-3300.1. Participation in collaborative agreements; regulations to be promulgated by the**
11 **Boards of Medicine and Pharmacy.**12 A. A pharmacist and his designated alternate pharmacists involved directly in patient care may participate
13 with (i) any person licensed to practice medicine, osteopathy, or podiatry together with any person licensed,
14 registered, or certified by a health regulatory board of the Department of Health Professions who provides
15 health care services to patients of such person licensed to practice medicine, osteopathy, or podiatry; (ii) a
16 physician's office as defined in § 32.1-276.3, provided that such collaborative agreement is signed by each
17 physician participating in the collaborative agreement; (iii) any licensed physician assistant working in
18 accordance with the provisions of § 54.1-2951.1; or (iv) any licensed advanced practice registered nurse
19 working in accordance with the provisions of § 54.1-2957, involved directly in patient care in collaborative
20 agreements which authorize cooperative procedures related to treatment using drug therapy, laboratory tests,
21 or medical devices, under defined conditions or limitations, for the purpose of improving patient outcomes
22 for patients who meet the criteria set forth in the collaborative agreement. However, no person licensed to
23 practice medicine, osteopathy, or podiatry, or licensed as an advanced practice registered nurse or physician
24 assistant, shall be required to participate in a collaborative agreement with a pharmacist and his designated
25 alternate pharmacists, regardless of whether a professional business entity on behalf of which the person is
26 authorized to act enters into a collaborative agreement with a pharmacist and his designated alternate
27 pharmacists.28 B. A patient who meets the criteria for inclusion in the category of patients whose care is subject to a
29 collaborative agreement and who chooses to not participate in a collaborative procedure shall notify the
30 prescriber of his refusal to participate in such collaborative procedure. A prescriber may elect to have a
31 patient not participate in a collaborative procedure by contacting the pharmacist or his designated alternate
32 pharmacists or by documenting the same on the patient's prescription.33 C. Collaborative agreements may include prescribing, modification, continuation, or discontinuation of
34 drug therapy pursuant to written or electronic protocols, provided implementation of drug therapy occurs
35 following diagnosis by the licensed physician, podiatrist, advanced practice registered nurse, registered nurse,
36 or physician assistant; the ordering of laboratory tests; or other patient care management measures related to
37 monitoring or improving the outcomes of drug or device therapy. No such collaborative agreement shall
38 exceed the scope of practice of the respective parties. Any pharmacist who deviates from or practices in a
39 manner inconsistent with the terms of a collaborative agreement shall be in violation of § 54.1-2902; such
40 violation shall constitute grounds for disciplinary action pursuant to §§ 54.1-2400 and 54.1-3316.41 D. Collaborative agreements may only be used for conditions which have protocols that are clinically
42 accepted as the standard of care, or are approved by the Boards of Medicine and Pharmacy. The Boards of
43 Medicine and Pharmacy shall jointly develop and promulgate regulations to implement the provisions of this
44 section and to facilitate the development and implementation of safe and effective collaborative agreements
45 between the appropriate practitioners and pharmacists. The regulations shall include guidelines concerning
46 the use of protocols, and a procedure to allow for the approval or disapproval of specific protocols by the
47 Boards of Medicine and Pharmacy if review is requested by a practitioner or pharmacist.48 E. Notwithstanding the provisions of §§ 54.1-3303 and 54.1-3408, a pharmacist may prescribe, modify,
49 continue, or discontinue Schedule II through VI controlled substances in accordance with this section.50 F. Prior to a pharmacist prescribing, modifying, continuing, or discontinuing a Schedule II through V
51 controlled substance in accordance with this section, the pharmacist shall submit proof of the signed
52 collaborative practice agreement to the Board and obtain authorization from the Board for such activity.

INTRODUCED

HB232